SpringerLink
Log in

Therapeutic Development in COVID-19

  • Chapter
  • First Online:
Coronavirus Disease - COVID-19

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1318))

Abstract

Since the outbreak of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2, the disease has spread rapidly worldwide and developed into a global pandemic, causing a significant impact on the global health system and economic development. Scientists have been racing to find effective drugs and vaccines for the treatment and prevention of COVID-19. However, due to the diversity of clinical manifestations caused by COVID-19, no standard antiviral regimen beyond supportive therapy has been established. Ongoing clinical trials are underway to evaluate the efficacy of drugs that primarily act on the viral replication cycle or enhanced immunity of patients. This chapter will summarize the currently used antiviral and adjuvant therapies in clinical practice and provide a theoretical basis for the future treatment of COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 192.59
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 246.09
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 246.09
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9(2). https://doi.org/10.1128/mBio.00221-18

  • Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, Guedes JS, Meneghetti MR, Krettli AU (2018) Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist 8(3):459–464. https://doi.org/10.1016/j.ijpddr.2018.10.002

    Article  PubMed  PubMed Central  Google Scholar 

  • Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Lunell A, Miro-Mur F (2020) Immunomodulatory therapy for the management of severe COVID-19. Beyond the antiviral therapy: a comprehensive review. Autoimmun Rev:102569. https://doi.org/10.1016/j.autrev.2020.102569

  • Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300(5626):1763–1767. https://doi.org/10.1126/science.1085658

    Article  PubMed  CAS  Google Scholar 

  • Antinori S, Bonazzetti C, Gubertini G, Capetti A, Pagani C, Morena V, Rimoldi S, Galimberti L, Sarzi-Puttini P, Ridolfo AL (2020) Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev:102564. https://doi.org/10.1016/j.autrev.2020.102564

  • Asakura H, Ogawa H (2020) Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14858

  • Aspiroz EL, Figueroa SEC, Hurle ADG, Sanchez MJG (2013) New strategies in the optimisation of lopinavir/ritonavir doses in human immunodeficiency virus-infected patients. Enferm Infec Micr Cl 31(1):36–43. https://doi.org/10.1016/j.eimc.2011.11.018

    Article  Google Scholar 

  • Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, Members A-SG (2020) Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2007764

  • Boonrod K, Galetzka D, Nagy PD, Conrad U, Krczal G (2004) Single-chain antibodies against a plant viral RNA-dependent RNA polymerase confer virus resistance. Nat Biotechnol 22(7):856–862. https://doi.org/10.1038/nbt983

    Article  PubMed  CAS  Google Scholar 

  • Bray M, Rayner C, Noel F, Jans D, Wagstaff K (2020) Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Res:104805. https://doi.org/10.1016/j.antiviral.2020.104805

  • Brooks MJ, Burtseva EI, Ellery PJ, Marsh GA, Lew AM, Slepushkin AN, Crowe SM, Tannock GA (2012) Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 84(1):170–181. https://doi.org/10.1002/jmv.22234

    Article  PubMed  CAS  Google Scholar 

  • Brown AJ, Won JJ, Graham RL, Dinnon KH 3rd, Sims AC, Feng JY, Cihlar T, Denison MR, Baric RS, Sheahan TP (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir Res 169:104541. https://doi.org/10.1016/j.antiviral.2019.104541

    Article  PubMed  CAS  Google Scholar 

  • Cai Q, Yang M, Liu D, Chen J, Shu D, **a J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L (2020) Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Bei**g). https://doi.org/10.1016/j.eng.2020.03.007

  • Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, **a J, Chen N, **ang J, Yu T, Bai T, **e X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787–1799. https://doi.org/10.1056/NEJMoa2001282

    Article  PubMed  Google Scholar 

  • Chafekar A, Fielding BC (2018) MERS-CoV: understanding the latest human coronavirus threat. Viruses 10(2). https://doi.org/10.3390/v10020093

  • Chen L, **ong J, Bao L, Shi Y (2020a) Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 20(4):398–400. https://doi.org/10.1016/S1473-3099(20)30141-9

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Chen X, Li R, Pan Z, Qian C, Yang Y, You R, Zhao J, Liu P, Gao L, Li Z, Huang Q, Xu L, Tang J, Tian Q, Yao W, Hu L, Yan X, Zhou X, Wu Y, Deng K, Zhang Z, Qian Z, Chen Y, Ye L (2020b) Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol 17(6):647–649. https://doi.org/10.1038/s41423-020-0426-7

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, Montecucco C, Mojoli F, Giusti EM, Bruno R, The Covid Irccs San Matteo Pavia Task F (2020) Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo Covid19 REgistry (SMACORE). Microorganisms 8(5). https://doi.org/10.3390/microorganisms8050695

  • Costanzo M, De Giglio MAR, Roviello GN (2020) SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. https://doi.org/10.2174/0929867327666200416131117

  • de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 117(12):6771–6776. https://doi.org/10.1073/pnas.1922083117

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Deeks ED (2018) Darunavir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs 78(10):1013–1024. https://doi.org/10.1007/s40265-018-0934-2

    Article  PubMed  CAS  Google Scholar 

  • Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, **a J (2020) Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Inf Secur. https://doi.org/10.1016/j.**f.2020.03.002

  • Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S (2017) MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 21(2):131–143. https://doi.org/10.1080/14728222.2017.1271415

    Article  PubMed  CAS  Google Scholar 

  • Fang QQ, Huang WJ, Li XY, Cheng YH, Tan MJ, Liu J, Wei HJ, Meng Y, Wang DY (2020) Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. Virology 545:1–9. https://doi.org/10.1016/j.virol.2020.02.005

    Article  PubMed  CAS  Google Scholar 

  • Fantini J, Di Scala C, Chahinian H, Yahi N (2020) Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents:105960. https://doi.org/10.1016/j.ijantimicag.2020.105960

  • Firstenberg MS, Stahel PF, Hanna J, Kotaru C, Crossno J Jr, Forrester J (2020) Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report. Patient Saf Surg 14:20. https://doi.org/10.1186/s13037-020-00245-7

    Article  PubMed  PubMed Central  Google Scholar 

  • Gao JJ, Tian ZX, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72–73. https://doi.org/10.5582/bst.2020.01047

    Article  PubMed  CAS  Google Scholar 

  • Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Tissot-Dupont HT, Honore S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D (2020) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis 34:101663. https://doi.org/10.1016/j.tmaid.2020.101663

    Article  PubMed  PubMed Central  Google Scholar 

  • Gong K, Xu Z, Cai Z, Chen Y, Wang Z (2020) Internet hospitals help prevent and control the epidemic of COVID-19 in China: multicenter user profiling study. J Med Internet Res 22(4):e18908. https://doi.org/10.2196/18908

    Article  PubMed  PubMed Central  Google Scholar 

  • Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D’Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2007016

  • Grossi PA, Lombardi D, Petrolo A, Rovelli C, Di Rosa Z, Perriccioli G, Rossi A, Minoja G, Scaglione F, Dalla Gasperina D (2018) Strongyloides stercoralis hyperinfection in an HIV-infected patient successfully treated with subcutaneous ivermectin. Trop Med Infect Dis 3(2). https://doi.org/10.3390/tropicalmed3020046

  • Ho M (2020) Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther 3(2):109–114. https://doi.org/10.1093/abt/tbaa009

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ho LTF, Chan KKH, Chung VCH, Leung TH (2020) Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19. Eur J Integr Med:101116. https://doi.org/10.1016/j.eujim.2020.101116

  • Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S (2020a) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271. https://doi.org/10.1016/j.cell.2020.02.052

  • Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S (2020b) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280 e278. https://doi.org/10.1016/j.cell.2020.02.052

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK, Washington State -nCo VCIT (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929–936. https://doi.org/10.1056/NEJMoa2001191

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS (2020) Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese Herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine:153242. https://doi.org/10.1016/j.phymed.2020.153242

  • Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, **a J, Wei Y, Wu W, **e X, Yin W, Li H, Liu M, **ao Y, Gao H, Guo L, **e J, Wang G, Jiang R, Gao Z, ** Q, Wang J, Cao B (2020a) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Huang J, Song W, Huang H, Sun Q (2020b) Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19. J Clin Med 9(4). https://doi.org/10.3390/jcm9041131

  • Huang X, Wei F, Hu L, Wen L, Chen K (2020c) Epidemiology and clinical characteristics of COVID-19. Arch Iran Med 23(4):268–271. https://doi.org/10.34172/aim.2020.09

  • Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A (2018) Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 18(8):e217–e227. https://doi.org/10.1016/S1473-3099(18)30127-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY (2020) Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. https://doi.org/10.1016/S0140-6736(20)31042-4

  • Janowski AB, Dudley H, Wang D (2020) Antiviral activity of ribavirin and favipiravir against human astroviruses. J Clin Virol 123:104247. https://doi.org/10.1016/j.jcv.2019.104247

    Article  PubMed  CAS  Google Scholar 

  • Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, **a Z (2020) Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 35(5):1545–1549. https://doi.org/10.1007/s11606-020-05762-w

    Article  PubMed  PubMed Central  Google Scholar 

  • ** Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, Liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, **ao G, Qin C, Shi Z, Jiang H, Rao Z, Yang H (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. https://doi.org/10.1038/s41586-020-2223-y

  • Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE (2020) Managing COVID-19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy. https://doi.org/10.1002/phar.2410

  • Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L (2020) Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. https://doi.org/10.1038/s41586-020-2380-z

  • Kannan S, Ali PSS, Sheeza A, Hemalatha K (2020) COVID-19 (novel coronavirus 2019) – recent trends. Eur Rev Med Pharmacol 24(4):2006–2011

    Google Scholar 

  • Keshavarzi F (2016) Fungistatic effect of hydroxychloroquine, lessons from a case. Med Mycol Case Rep 13:17–18. https://doi.org/10.1016/j.mmcr.2016.09.003

    Article  PubMed  PubMed Central  Google Scholar 

  • Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y (2020) Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol. https://doi.org/10.1002/jmv.25798

  • Khavandi S, Tabibzadeh E, Naderan M, Shoar S (2020) Corona virus disease-19 (COVID-19) presenting as conjunctivitis: atypically high-risk during a pandemic. Cont Lens Anterior Eye. https://doi.org/10.1016/j.clae.2020.04.010

  • Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, Kim SH (2020) Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2020.04.040

  • Klimke A, Hefner G, Will B, Voss U (2020) Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. Med Hypotheses 142:109783. https://doi.org/10.1016/j.mehy.2020.109783

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lian N, **e H, Lin S, Huang J, Zhao J, Lin Q (2020) Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2020.04.026

  • Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, Liu XQ, Sang L, Chen RC, Tang CL, Wang T, Wang W, He QH, Chen ZS, Wong SS, Zanin M, Liu J, Xu X, Huang J, Li JF, Ou LM, Cheng B, **ong S, **e ZH, Ni ZY, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX (2020) Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): a nationwide analysis of China. Eur Respir J. https://doi.org/10.1183/13993003.00562-2020

  • Liu X, Na RS, Bi ZQ (2020) Challenges to prevent and control the outbreak of novel coronavirus pneumonia (COVID-19). Zhonghua Liu **ng Bing Xue Za Zhi 41:E029. https://doi.org/10.3760/cma.j.cn112338-20200216-00108

  • Lythgoe MP, Middleton P (2020) Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci 41(6):363–382. https://doi.org/10.1016/j.tips.2020.03.006

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mahase E (2020) Covid-19: Remdesivir is helpful but not a wonder drug, say researchers. Bmj-Brit Med J:369. https://doi.org/10.1136/bmj.m1798

  • Martinez MA (2020) Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Ch 64 (5):ARTN e00399-20. https://doi.org/10.1128/AAC.00399-20

  • Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, Lionello R, Marrazzo G, Lagana D, Costanzo FS, Matera G, Trecarichi EM, Torti C, Group IUC (2020) Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. J Med Virol. https://doi.org/10.1002/jmv.26016

  • Mo S, Chen D (2019) Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Eur J Immunol 49:564–564

    CAS  Google Scholar 

  • Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H (2020) Newly diagnosed glomerulonephritis during COVID-19 infection undergoing immunosuppression therapy, a case report. Iran J Kidney Dis 14(3):239–242

    PubMed  Google Scholar 

  • Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905–913 e907. https://doi.org/10.1016/j.cell.2020.04.004

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ni L, Zhou L, Zhou M, Zhao J, Wang DW (2020) Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front Med 14(2):210–214. https://doi.org/10.1007/s11684-020-0757-x

    Article  PubMed  Google Scholar 

  • Patri A, Fabbrocini G (2020) Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol 82(6):e221. https://doi.org/10.1016/j.jaad.2020.04.017

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Peiris JS, Guan Y, Yuen KY (2004) Severe acute respiratory syndrome. Nat Med 10(12 Suppl):S88–S97. https://doi.org/10.1038/nm1143

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, El-Gamal Y, Harville TO, Hossny E, Mazer B, Nelson R, Secord E, Jordan SC, Stiehm R, Vo AA, Ballow M (2017) Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol 139(3):S1–S46. https://doi.org/10.1016/j.jaci.2016.09.023

    Article  PubMed  CAS  Google Scholar 

  • Pilkington V, Pepperrell T, Hill A (2020) A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad 6(2):45–51

    Google Scholar 

  • Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Invest 38(8):653–671. https://doi.org/10.1007/s40261-018-0656-y

    Article  CAS  Google Scholar 

  • Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, Dhama K, Yatoo MI, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020) SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med 28(2):174–184

    PubMed  CAS  Google Scholar 

  • Rajic KPZ, Mlinaric Z, Uzelac L, Kralj M, Zorc B (2018) Chloroquine urea derivatives: synthesis and antitumor activity in vitro. Acta Pharma 68(4):471–483. https://doi.org/10.2478/acph-2018-0039

    Article  CAS  Google Scholar 

  • Ruan G, Ye L, Liu G, An J, Sehouli J, Sun P (2018) The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. Onco Targets Ther 11:521–528. https://doi.org/10.2147/OTT.S155581

    Article  PubMed  PubMed Central  Google Scholar 

  • Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, ** Z, Zhenhua J, Haiming J, Kui Z, Shuxiang H, Jun D, **aobo L, **aotao H, Lin W, Nanshan Z, Zifeng Y (2020) Lianhuaqingwen exerts antiviral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 156:104761. https://doi.org/10.1016/j.phrs.2020.104761

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 209:107512. https://doi.org/10.1016/j.pharmthera.2020.107512

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Singh AK, Singh A, Shaikh A, Singh R, Misra A (2020a) Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other develo** countries. Diabetes Metab Syndr 14(3):241–246. https://doi.org/10.1016/j.dsx.2020.03.011

    Article  PubMed  PubMed Central  Google Scholar 

  • Singh AK, Singh A, Singh R, Misra A (2020b) Hydroxychloroquine in patients with COVID-19: a systematic review and meta-analysis. Diabetes Metab Syndr 14(4):589–596. https://doi.org/10.1016/j.dsx.2020.05.017

    Article  PubMed  PubMed Central  Google Scholar 

  • Sk MF, Roy R, Jonniya NA, Poddar S, Kar P (2020) Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations. J Biomol Struct Dyn:1–21. https://doi.org/10.1080/07391102.2020.1768149

  • Stadler K, Rappuoli R (2005) SARS: understanding the virus and development of rational therapy. Curr Mol Med 5(7):677–697. https://doi.org/10.2174/156652405774641124

    Article  PubMed  CAS  Google Scholar 

  • Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE (2020) Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care 29 (Sup5a):S4–S8. https://doi.org/10.12968/jowc.2020.29.Sup5a.S4

  • Tian X, Li C, Huang A, **a S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, Ying T (2020) Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 9(1):382–385. https://doi.org/10.1080/22221751.2020.1729069

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Trinh R, Gathe J, Reynes J, Pulido F, Tian M, Fredrick L, Podsadecki T, Norton M, Nilius A (2012) Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) in antiretroviral-naive subjects: 96-week safety and efficacy results of the PROGRESS study. HIV Med 13:69–69

    Google Scholar 

  • Tsang K, Zhong NS (2003) SARS: pharmacotherapy. Respirology 8(Suppl):S25–S30. https://doi.org/10.1046/j.1440-1843.2003.00525.x

    Article  PubMed  Google Scholar 

  • Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA (2012) Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 443(3):851–856. https://doi.org/10.1042/BJ20120150

    Article  PubMed  CAS  Google Scholar 

  • Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, van Kuppeveld FJM, Haagmans BL, Grosveld F, Bosch BJ (2020a) A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11(1):2251. https://doi.org/10.1038/s41467-020-16256-y

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, **ao G (2020b) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271. https://doi.org/10.1038/s41422-020-0282-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang M, Li R, Shu B, **g X, Ye HQ, Gong P (2020c) Stringent control of the RNA-dependent RNA polymerase translocation revealed by multiple intermediate structures. Nat Commun 11(1):2605. https://doi.org/10.1038/s41467-020-16234-4

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang ML, Cao RY, Zhang LK, Yang XL, Liu J, Xu MY, Shi ZL, Hu ZH, Zhong W, **ao GF (2020d) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271. https://doi.org/10.1038/s41422-020-0282-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wen CY, **e ZW, Li YP, Deng XL, Chen XT, Cao Y, Ou X, Lin WY, Li F, Cai WP, Li LH (2020) Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19: an observational cohort study. Zhonghua Nei Ke Za Zhi 59(0):E012. https://doi.org/10.3760/cma.j.cn112138-20200227-00147

  • Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, Gong Y, **ao H, Fan Z, Tan S, Wu G, Tan W, Lu X, Fan C, Wang Q, Liu Y, Zhang C, Qi J, Gao GF, Gao F, Liu L (2020) A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368(6496):1274–1278. https://doi.org/10.1126/science.abc2241

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Yang JC, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV (2018) Population pharmacokinetics of lopinavir/ritonavir: changes across formulations and human development from infancy through adulthood. J Clin Pharmacol 58(12):1604–1617. https://doi.org/10.1002/jcph.1293

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Yang R, Liu H, Bai C, Wang Y, Zhang X, Guo R, Wu S, Wang J, Leung E, Chang H, Li P, Liu T, Wang Y (2020) Chemical composition and pharmacological mechanism of Qingfei Paidu decoction and Ma **ng Shi Gan decoction against coronavirus disease 2019 (COVID-19): in silico and experimental study. Pharmacol Res 157:104820. https://doi.org/10.1016/j.phrs.2020.104820

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ye XT, Luo YL, **a SC, Sun QF, Ding JG, Zhou Y, Chen W, Wang XF, Zhang WW, Du WJ, Ruan ZW, Hong L (2020) Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus disease 2019. Eur Rev Med Pharmacol Sci 24(6):3390–3396. https://doi.org/10.26355/eurrev_202003_20706

    Article  PubMed  Google Scholar 

  • Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G, Villanueva EV (2020) Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust 212(9):416–420. https://doi.org/10.5694/mja2.50577

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhao X, Jiang Y, Zhao Y, ** H, Liu C, Qu F, Feng X (2020) Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur J Clin Microbiol Infect Dis. https://doi.org/10.1007/s10096-020-03897-6

  • Zhou GY, Zhao Q (2020) Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci 16(10):1718–1723. https://doi.org/10.7150/ijbs.45123

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pohlmann S, McKerrow JH, Renslo AR, Simmons G (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antivir Res 116:76–84. https://doi.org/10.1016/j.antiviral.2015.01.011

    Article  PubMed  CAS  Google Scholar 

  • Zhou Y, Yang Y, Huang J, Jiang S, Du L (2019) Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses 11(1). https://doi.org/10.3390/v11010060

  • Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J, Xue Y (2020) Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Inf Secur. https://doi.org/10.1016/j.**f.2020.03.060

  • Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH, 2nd, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J, lung-network@humancellatlas.org HCALBNEa, Network HCALB (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. https://doi.org/10.1016/j.cell.2020.04.035

Download references

Author information

Authors and Affiliations

  1. Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China

    Chan Yang, Yuan Huang & Shuwen Liu

  2. State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou, China

    Shuwen Liu

  3. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Guangzhou, China

    Shuwen Liu

Authors
  1. Chan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuwen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuwen Liu .

Editor information

Editors and Affiliations

  1. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yang, C., Huang, Y., Liu, S. (2021). Therapeutic Development in COVID-19. In: Rezaei, N. (eds) Coronavirus Disease - COVID-19. Advances in Experimental Medicine and Biology, vol 1318. Springer, Cham. https://doi.org/10.1007/978-3-030-63761-3_25

Download citation

Publish with us

Policies and ethics

Search

Navigation